Patents by Inventor Marie-Christine Multon

Marie-Christine Multon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for identifying an antagonist of guanine nucleotide releasing factor 1
    Patent number: 8852878
    Abstract: The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: October 7, 2014
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Michel Itier, Marie-Christine Multon, Gwénaëlle Ret, Jean-Marie Stutzmann, Florence Wahl
  • USE OF GRF1 PROTEIN FOR SCREENING MOLECULES
    Publication number: 20120009604
    Abstract: The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease.
    Type: Application
    Filed: August 3, 2011
    Publication date: January 12, 2012
    Applicant: AVENTIS PHARMA SA
    Inventors: Jean-Michel ITIER, Marie-Christine MULTON, Gwénaëlle RET, Jean-Marie STUTZMANN, Florence WAHL
  • Net, a transcription factor of the TCF family, as regulator of angiogenic factor expression
    Patent number: 7537887
    Abstract: The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: May 26, 2009
    Assignees: Aventis Pharma S.A., Institut National de la Sante de la Recherche Medicale
    Inventors: Bohdan Wasylyk, Marie-Christine Multon, Abdelkader Ayadi, Hong Zheng
  • MEKK1-interacting FHA protein 1 (MIF1)
    Patent number: 7364871
    Abstract: The present invention relates to a novel protein of the MEKK signal transduction pathway, and the gene encoding it. The invention further relates to diagnostic and therapeutic uses of the protein or the gene, and to methods of screening for agonists or antagonists of the protein, particularly with respect to MEKK activity. In particular, the invention provides a gene encoding MIF1, the MIF1 protein, and antibodies that specifically bind MIF1. MIF1 and the MIF1 gene can be used in screening assays, particularly to identify agonists and antagonists of MIF1 interaction with MEKK, and thus modulators of the MEKK signal pathway. MIF1 gene (or cDNA) can also be delivered to cells, e.g., for in vitro screening or testing, or in vivo or ex vivo for gene therapy.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: April 29, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Christophe Marcireau, Marie-Christine Multon, Valerie Polard-Housset
  • MEKK1-interacting FHA protein 1 (MIF1)
    Publication number: 20050250143
    Abstract: The present invention relates to a novel protein of the MEKK signal transduction pathway, and the gene encoding it. The invention further relates to diagnostic and therapeutic uses of the protein or the gene, and to methods of screening for agonists or antagonists of the protein, particularly with respect to MEKK activity. In particular, the invention provides a gene encoding MIF1, the MIF1 protein, and antibodies that specifically bind MIF1. MIF1 and the MIF1 gene can be used in screening assays, particularly to identify agonists and antagonists of MIF1 interaction with MEKK, and thus modulators of the MEKK signal pathway. MIF1 gene (or cDNA) can also be delivered to cells, e.g., for in vitro screening or testing, or in vivo or ex vivo for gene therapy.
    Type: Application
    Filed: April 14, 2005
    Publication date: November 10, 2005
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Christophe Marcireau, Marie-Christine Multon, Valerie Polard-Housset
  • Use of grf1 protein for screening molecules
    Publication number: 20050100972
    Abstract: The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease.
    Type: Application
    Filed: August 7, 2001
    Publication date: May 12, 2005
    Inventors: Jean-Michel Itier, Marie-Christine Multon, Gwenaelle Ret, Jean-Marie Stutzmann, Florence Wahl
  • MEKK1 (serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (M1F1)
    Patent number: 6890733
    Abstract: The present invention relates to a novel protein of the MEKK signal transduction pathway, and the gene encoding it. The invention further relates to diagnostic and therapeutic uses of the protein or the gene, and to methods of screening for agonists or antagonists of the protein, particularly with respect to MEKK activity. In particular, the invention provides a gene encoding MIF1, the MIF1 protein, and antibodies that specifically bind MIF1. MIF1 and the MIF1 gene can be used in screening assays, particularly to identify agonists and antagonists of MIF1 interaction with MEKK, and thus modulators of the MEKK signal pathway. MIF1 gene (or cDNA) can also be delivered to cells, e.g., for in vitro screening or testing, or in vivo or ex vivo for gene therapy.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: May 10, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Christophe Marcireau, Marie-Christine Multon, Valerie Polard-Housset
  • Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
    Publication number: 20040053833
    Abstract: The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.
    Type: Application
    Filed: October 3, 2003
    Publication date: March 18, 2004
    Inventors: Bohdan Wasylyk, Marie-Christine Multon, Abdelkader Ayadi, Hong Zheng